Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)

被引：0

作者：

Lin, Jeffrey

Mortazavi, Amir

Stein, Mark N.

Pal, Sumanta K.

Davarpanah, Nicole N.

Nadal, Rosa Maria

Francis, Deneise C.

Berniger, Marilise Anne

Monk, Paul

Kempf, Jeffrey

Becker, Murray

Sokol, Levi

McKinney, Yolanda

Knopp, Michael V.

Wright, Chadwick

Jung, Alex

Choyke, Peter L.

Mena, Esther

Lindenberg, Liza

Apolo, Andrea B.

机构：

[1] NIH, NCI, Genitourinary Malignancies Branch, Ctr Canc Res, Bethesda, MD USA

[2] Ohio State Univ, Arthur G James Canc Hosp, Wexner Med Ctr, Columbus, OH USA

[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[4] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA

[5] NIH, Bethesda, MD USA

[6] NCI, Leidos Biomed Inc, Bethesda, MD USA

[7] Ohio State Univ, Columbus, OH USA

[8] Rutgers Robert Wood Johnson Med Sch, Newark, NJ USA

[9] Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA

[10] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] NIH, NCI, Bethesda, MD USA

[13] NIH, NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA

[14] NIH, Washington, DC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e16017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16017

引用

页数：6

共 50 条

[21] Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) plus ipilimumab (ipi) plus external beam radiotherapy (RT) in patients with metastatic melanoma.
Postow, Michael A.
Knox, Susan Jane
Goldman, Debra
Panageas, Katherine
Halpenny, Darragh
McCabe, Danielle
Macri, Mary J.
Schwarzenberger, Paul
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph Rudolph
Barker, Christopher Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
Gupta, Ruby
Ornstein, Moshe Chaim
Gul, Anita
Allman, Kimberly D.
Ball, Jessica
Wood, Laura S.
Garcia, Jorge A.
VonMerveldt, Dendra
Hammers, Hans J.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[23] Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Najjar, Yana G.
Navrazhina, Kristina
Ding, Fei
Bhatia, Roma
Tsai, Katy
Abbate, Kelly
Durden, Barbara
Eroglu, Zeynep
Bhatia, Shailender
Park, Song
Chowdhary, Akansha
Chandra, Sunandana
Kennedy, Jonathan
Ernstoff, Marc
Vachhani, Pankit
Drabick, Joseph
Singh, Arun
Xu, Tan
Yang, Jessica
Carvajal, Richard
Manson, Daniel
Kirkwood, John
Cohen, Justine
Sullivan, Ryan
Johnson, Douglas
Funchain, Pauline
Shoushtari, Alexander
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[24] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
Gupta, Ruby
Ornstein, Moshe Chaim
Gul, Anita
Allman, Kimberly D.
Ball, Jessica
Wood, Laura S.
Garcia, Jorge A.
VonMerveldt, Dendra
Hammers, Hans J.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[25] Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
Shoushtari, Alexander Noor
Navid-Azarbaijani, Pedram
Friedman, Claire Frances
Panageas, Katherine
Postow, Michael Andrew
Callahan, Margaret K.
Momtaz, Parisa
Campbell, Shonnette C.
Shames, Yelena
Prempeh-Keteku, Nana A.
Nwaedozie, Kasiemobi
Wolchok, Jedd D.
Chapman, Paul B.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).
Grewal, Kabir
Chauhan, Pankaj Kumar
Mukhida, Sagar S.
Tannir, Nizar M.
Venkatesh, Neha
Shah, Amishi Yogesh
Zurita, Amado J.
Johns, Andrew
Campbell, Matthew T.
Goswami, Sangeeta
Gao, Jianjun
Jonasch, Eric
Mcquade, Jennifer Leigh
Alhalabi, Omar
Msaouel, Pavlos
Hahn, Andrew Warren
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545
[27] Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).
Zhang, Tian
Wu, Yuan
Agarwal, Anika
Starr, Mark D.
Reyes-Martinez, Marco
Anand, Monika
Runyambo, Daniella
Harrison, Michael Roger
Armstrong, Andrew J.
George, Daniel J.
Nixon, Andrew B.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[28] Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Girardi, Daniel da Motta
Niglio, Scot Anthony
Mortazavi, Amir
Lara, Primo
Pal, Sumanta K.
Saraiya, Biren
Cordes, Lisa M.
Ley, Lisa
Ortiz, Olena Sierra
Cadena, Jacqueline
Diaz, Carlos
Bagheri, Mohammadhadi H.
Steinberg, Seth M.
Costello, Rene
Streicher, Howard
Wright, John
Parnes, Howard L.
Ning, Yang-Min
Bottaro, Donald P.
Apolo, Andrea B.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Efficacy and safety of nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
Naumann, R. W.
Oaknin, A.
Meyer, T.
Lopez-Picazo, J. M.
Lao, C.
Bang, Y-J.
Boni, V.
Sharfman, W. H.
Park, J. C.
Devriese, L. A.
Harano, K.
Chung, C. H.
Topalian, S. L.
Zaki, K.
Chen, T.
Gu, J.
Li, B.
Barrows, A.
Horvath, A.
Moore, K. N.
ANNALS OF ONCOLOGY, 2019, 30 : 898 - +
[30] Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma
Gibney, Geoffrey Thomas
Pecora, Andrew L.
Rapisuwon, Suthee
Chen, Kevin
Gardner, Kellie
Cramer, Gayle
Blair, Danielle
Avergas, Amy
Swanson, Nicole
Ahn, Jaeil
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →